Trials / Completed
CompletedNCT04265755
Biomarker and Genetic Predictors of Erenumab Treatment Response
Biomarker and Genetic Predictors of Erenumab Treatment Response, a Phase 4 Investigational Open-label Study (INTERROGATE)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,406 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
To explore the relationship between clinical response to erenumab and genetic biomarkers
Detailed description
This is a phase 4 open-label study aiming to explore the relationship between clinical response to erenumab and genetic biomarkers. Subjects with episodic or chronic migraine will be treated with Erenumab 70mg or 140mg for a 4-week baseline/screening period, followed by a 24-week treatment period. Subjects will collect migraine-related parameters daily using an eDiary and blood samples will be collected for biomarker research. All analysis will be descriptive in nature.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Erenumab | Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI). |
Timeline
- Start date
- 2020-10-26
- Primary completion
- 2023-01-18
- Completion
- 2023-01-18
- First posted
- 2020-02-12
- Last updated
- 2024-06-07
- Results posted
- 2024-06-07
Locations
2 sites across 2 countries: Denmark, Iceland
Source: ClinicalTrials.gov record NCT04265755. Inclusion in this directory is not an endorsement.